Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8038478 | 0.91 | GPR119 (0.51) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL633472 | 0.90 | NR1H2 (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL7926868 | 0.90 | NR1H2 (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL633471 | 0.90 | NR1H2 (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL310276 | 0.88 | HPGD (0.53) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL447042 | 0.88 | HPGD (0.55) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL5341727 | 0.86 | HPGD (0.54) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL15085735 | 0.86 | HPGD (0.57) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL1490070 | 0.85 | GPR119 (0.54) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL12082 | 0.84 | HPGD (0.55) | HPGDKDM4EPKMRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 237 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026098309-A1 | POLYCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4737470-A2 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | Zikani Therapeutics, Inc. (US) | 2026-05-06 | — | — | EP | disclosed |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | Zikani Therapeutics , Inc. (US) | 2026-02-17 | — | — | US | disclosed |
| EP-3883647-B1 | C10-ALKYLENE SUBSTITUTED 13-MEMBERED MACROLIDES AND USES THEREOF | ZIKANI THERAPEUTICS INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | INCYTE CORPORATION (US) | 2026-01-27 | — | — | US | disclosed |
| EP-4676927-A1 | HETEROCYCLIC COMPOUNDS AS WRN INHIBITORS | Synnovation Therapeutics, Inc. (US) | 2026-01-14 | — | — | EP | disclosed |
| EP-4673441-A1 | LZK INHIBITORS | Ureka Bioscienes, Inc. (US) | 2026-01-07 | — | — | EP | disclosed |
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | VOLASTRA THERAPEUTICS, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025245472-A1 | COMPOUNDS AND RELATED METHODS USEFUL FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-11-27 | — | — | WO | disclosed |
| WO-2025227032-A1 | METHODS FOR DEGRADATION OF CYCLIN K AND INHIBITION OF CYCLIN DEPENDENT KINASES | REMIX THERAPEUTICS INC. (US) | 2025-10-30 | — | — | WO | disclosed |
| EP-0512831-B1 | Fibrinogen receptor antagonists | MERCK & CO INC (US) | 1999-09-22 | — | — | EP | disclosed |
| US-5773465-A | Tartronic acids, their acetalic ethers and o-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1998-06-30 | — | — | US | disclosed |
| US-5656656-A | Tartronic acids, their acetalic ethers and O-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1997-08-12 | — | — | US | disclosed |
| EP-0667850-B1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE FARMACEUTICI SPA (IT) | 1997-05-28 | — | — | EP | disclosed |
| US-5455243-A | Anticoagulants | MERCK & CO., INC. (US) | 1995-10-03 | — | — | US | disclosed |
| EP-0667850-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. | DOMPE FARMACEUTICI SPA (IT) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010127-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1994-05-11 | — | — | WO | disclosed |
| US-5281585-A | Secondary amide containing antagonist | MERCK & CO., INC. (US) | 1994-01-25 | — | — | US | disclosed |
| WO-1992019595-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1992-11-12 | — | — | WO | disclosed |
| EP-0512831-A1 | Fibrinogen receptor antagonists | MERCK & CO. INC. (US) | 1992-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12534463-B2 | Substituted tricyclic compounds as FGFR inhibitors | FGFR3, FGFR1, FGFR4 | HPGD 4218/4885KDM4E 756/4885PKM 2141/4885 |
| US-12552825-B2 | C10-alkylene substituted 13-membered macrolides and uses thereof | MALT1, NR3C2, MRPL21 | HPGD 2776/4885KDM4E 4022/4885PKM 4601/4885 |
| US-20250368654-A1 | HETEROCYCLIC INHIBITORS OF ENPP1 | ENPP1, ENPP3, ENPP2 | HPGD 442/4885KDM4E 3082/4885PKM 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.